Scientific deep-dive
Does Wegovy Cause Hair Loss? What the FDA Label Says (2026)
Wegovy's label: hair loss in 3.3% on 2.4 mg vs 1% on placebo (4% of women, 0.9% of men), 5.8% on 7.2 mg. When shedding starts and what helps.
Yes — Wegovy can cause hair loss, and its own prescribing information says so: in the pooled 68-week adult weight-loss trials, 3.3% of people on Wegovy 2.4 mg reported hair loss versus 1% on placebo, and the label states these reactions “were associated with weight reduction”[1]. Almost all of it was in women (4% of women vs 0.9% of men), the rate climbed to 5.8% on the newer 7.2 mg dose[1], and the pattern fits telogen effluvium — a temporary, nonscarring shed that follows rapid weight loss — rather than damage to the follicle[8][10]. Below: exactly what the Wegovy label reports, how the STEP trials' weight loss lines up with that number, when shedding tends to show up relative to the 16-week dose climb, and what to do about it.
What the Wegovy label actually reports
Wegovy is semaglutide approved for chronic weight management (plus cardiovascular risk reduction and, as an injection, MASH). Its label lists hair loss among the most common adverse reactions in Section 6.1 and gives a dedicated paragraph with the sex breakdown. The adult figure comes from a pool of the label's Studies 2, 3 and 4 — registered as NCT03548935, NCT03552757 and NCT03611582, which are STEP 1, STEP 2 and STEP 3 in the published literature[2][3][4]. The wording, verbatim:
“Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction. In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male). In a pediatric trial, hair loss was reported in 4% of patients treated with 2.4 mg of WEGOVY and no placebo-treated patients.”— WEGOVY prescribing information, Section 6.1 (DailyMed)
| Trials (label) | Wegovy | Placebo | Women / men on Wegovy |
|---|---|---|---|
| Adults, 2.4 mg — Studies 2–4 (STEP 1–3), 68 weeks | 3.3% | 1% (2% of women, 0 men) | 4% / 0.9% |
| Adults, 7.2 mg trials (STEP UP program), 72 weeks | 5.8% on 7.2 mg; 3.3% on 2.4 mg | 1.0% (1.5% of women, 0 men) | 7.2 mg: 8.4% / 0.2%; 2.4 mg: 5.4% / 0 |
| Adolescents 12+, 2.4 mg (STEP TEENS), 68 weeks | 4% | 0 | Not broken out |
| Adults, 25 mg tablet (Study 7), 64 weeks | No separate hair-loss figure | — | Label says the common reactions were similar in type and frequency to those in the injection trials |
Two details in that section are easy to miss. First, in the 7.2 mg trials hair loss was the reason for one permanent discontinuation, one temporary interruption and five dose reductions in the 7.2 mg group, versus none of these in the 2.4 mg or placebo groups[1] — so at the top dose it occasionally changed treatment, but rarely. Second, the adolescent rate (4% vs 0) comes from the 201-participant STEP TEENS trial, in which BMI fell 16.1% on semaglutide versus a 0.6% rise on placebo over 68 weeks[7][1].
Magnitude comparison
Hair loss reported in the Wegovy 7.2 mg trials, by dose and sex (Wegovy prescribing information, Section 6.1). Nearly every case was in women; the rate rises with dose.[1]
- Placebo — women1.5 %
- Wegovy 2.4 mg — women5.4 %
- Wegovy 7.2 mg — women8.4 %
- Placebo — men0.0 %Zero on this scale
- Wegovy 2.4 mg — men0.0 %Zero on this scale
- Wegovy 7.2 mg — men0.2 %
Why women see it far more often on Wegovy
The sex gap is the most striking thing in the Wegovy data. In the 2.4 mg pool, women on Wegovy reported hair loss at twice the female placebo rate (4% vs 2%), while men barely registered (0.9% vs none). In the 7.2 mg trials the split widened: 8.4% of women versus 0.2% of men[1]. Because the STEP trials enrolled mostly women — 74% in STEP 1 and 81% in STEP 3, per the label's trial descriptions — the headline 3.3% blends a higher female rate with a near-zero male one. A woman deciding about Wegovy should read the 4% (2.4 mg) or 8.4% (7.2 mg) figure as her number.
The label does not explain the gap, and neither should we overstate it. What outside evidence shows is consistent: a systematic review of GLP-1 drugs and hair loss found women disproportionately affected[10], and a Korean dermatology clinic's review of 140 people with weight-loss telogen effluvium (110 of them women) concluded that women and older adults are especially vulnerable even when they lose no more weight than men[9].
How much weight Wegovy removes — and why the hair number follows it
The label ties Wegovy's hair loss to weight reduction, so the size of that reduction matters. At 68 weeks, average weight change on Wegovy 2.4 mg versus placebo was[1]:
- STEP 1 (obesity or overweight with a comorbidity): −14.9% vs −2.4%[2].
- STEP 2 (adults with type 2 diabetes): −9.6% vs −3.4% — the label notes Wegovy produced less weight reduction in people with type 2 diabetes[3][1].
- STEP 3 (with intensive behavioral therapy and an initial low-calorie diet): −16% vs −5.7%[4].
- STEP UP (72 weeks): −18.7% on 7.2 mg vs −15.6% on 2.4 mg and −3.9% on placebo in the published trial[6].
Line those up with the hair figures and the direction is the same: more weight off, more shedding reported — 3.3% at 2.4 mg, 5.8% at 7.2 mg. A useful benchmark from outside the drug world: in the Korean weight-loss telogen effluvium series, patients had lost an average of about 15% of body weight, at roughly 3.5 kg a month, before the shed brought them in[9]. That is almost exactly the average loss STEP 1 produced on Wegovy 2.4 mg, which helps explain why a 2.4 mg weight-management dose sits in a different hair-loss bracket than lower diabetes doses of the same molecule. The GLP-1 systematic review made the same observation from the other side: semaglutide-associated hair loss looked dose-dependent, with doses under 2 mg weekly rarely implicated[10]. (For what Ozempic's own label says, see Ozempic and hair loss; for the molecule across every product, see semaglutide and hair loss.)
Timing: the 16-week dose climb and when shedding shows up
Wegovy injection starts low and steps up every four weeks: 0.25 mg in weeks 1–4, 0.5 mg in weeks 5–8, 1 mg in weeks 9–12, 1.7 mg in weeks 13–16, then a maintenance dose from week 17 — 2.4 mg recommended, 1.7 mg allowed. People who have tolerated 2.4 mg for at least four weeks and need more weight loss can go up to 7.2 mg[1].
Telogen-type shedding lags its trigger. A 2026 systematic review of GLP-1 hair loss puts the expected delay at roughly 2–3 months after starting treatment, and 1.5–3 months after starting or increasing a dose if the shed is weight-loss telogen effluvium[10]. On the Wegovy schedule, that window lands in the back half of the titration and the first weeks at maintenance — months 2 to 4 of treatment. The same logic means a later step from 2.4 mg to 7.2 mg can start a fresh window a couple of months afterward.
Recovery tends to follow the weight curve, not the calendar. The same review reports that telogen effluvium typically improves within 3–6 months once weight stabilizes[10]. On Wegovy, weight keeps changing long after the 16-week titration — STEP 1 measured its main result at week 68[2] — so the shed may not settle until your weight does.
Should you stop Wegovy because of hair loss?
You and your prescriber should make that call together, but the evidence argues against stopping by reflex. The STEP 4 withdrawal trial (the label's Study 5) shows what happens to the weight: after a 20-week run-in to 2.4 mg, people switched to placebo regained 6.9% of their body weight over the next 48 weeks, while those who stayed on Wegovy lost another 7.9%[5][1]. Stopping does not pull hairs already in the resting phase back into growth, and a 2026 meta-analysis of GLP-1 alopecia specifically advised clinicians to avoid premature discontinuation, focusing on nutrition and counseling instead[11].
The label does offer room to adjust: the weight-management maintenance dose can be 1.7 mg rather than 2.4 mg, and moving to 7.2 mg is optional[1]. In the 7.2 mg trials, five people had their dose reduced because of hair loss[1]. If shedding is distressing, asking whether to hold at your current dose rather than stepping up is a reasonable conversation to have.
The mechanism, briefly
At any moment about 85% of scalp hairs are growing (anagen) and about 15% are resting (telogen). A significant metabolic stress can push a large share of growing hairs into the resting phase at once; they fall out together weeks later. Crash dieting, low protein intake and iron deficiency are all listed triggers[8]. The hair loss is nonscarring, so the follicles stay intact.
For Wegovy, the GLP-1 review authors suggest the driver may be the calorie restriction itself — too little energy and protein reaching the hair matrix — rather than the weight change alone[10]. That points to something you can influence: how much you eat while your appetite is suppressed. The review found no strong evidence that GLP-1 drugs permanently damage hair follicles[10].
What helps while you stay on Wegovy
- Don't let appetite suppression become a crash diet. Prevention strategies in the GLP-1 hair-loss literature start with avoiding dramatic weight loss and severe calorie restriction[10]. If you're eating far less than you did before Wegovy, that's worth raising with your prescriber or a dietitian.
- Prioritize protein and key micronutrients. The same review lists adequate protein, iron, zinc, vitamin D, B12 and vitamin A[10]. Our GLP-1 protein calculator turns your weight into a daily gram target.
- Ask about basic labs if shedding persists. A complete blood count, ferritin, TSH and vitamin D are the suggested starting panel, especially after rapid loss or very low intake[10]. Don't start high-dose iron without a test.
- Check the pattern. Diffuse shedding all over the scalp, hairs that come out easily on a gentle pull, and no patterned thinning point to telogen effluvium; patterned thinning points to androgenetic (pattern) hair loss, which has its own treatments such as topical minoxidil[10]. Our review of finasteride and minoxidil on GLP-1s covers that evidence.
- Track your week. The GLP-1 side-effect timeline shows where hair loss usually falls relative to other Wegovy side effects.
When to see a clinician
- Round, patchy bald spots. That suggests alopecia areata, a separate autoimmune condition; the 2026 meta-analysis did not find a significant link between GLP-1 drugs and alopecia areata[11], so don't assume Wegovy is the cause.
- Red, painful, shiny or smooth patches. Telogen effluvium is nonscarring[8]; scarring hair loss needs a dermatologist promptly.
- Patterned thinning rather than diffuse shedding — more consistent with androgenetic alopecia, which the 2026 meta-analysis did associate with GLP-1 use[11].
- Shedding that keeps going after your weight has leveled off — a reason for the lab panel above[10].
How Wegovy compares with the other brands: Zepbound and Mounjaro (tirzepatide) each have their own label figures, and the GLP-1 hair loss overview puts every label side by side. Prescribing details for the drug itself are on the Wegovy drug page.
Our reviews
Providers that offer semaglutide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 8.3. Read our review of CoreAge RxLowest-price compounded semaglutide and tirzepatide with one flat price at every doseFrom$79/mostarting pricecompounded
- Editorial score: 8.3. Read our review of CollectiveThe lowest flat medication price if you can absorb an annual membership feeFrom$59/mo+ required membershipcompounded
- Editorial score: 8.3. Read our review of FoundMedication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1sFrom$169/mo12-month plan ratecompounded
- Editorial score: 6.9. Read our review of YourEraFlat month-to-month pricing on compounded GLP-1s at every doseFrom$89/mocompounded
- Editorial score: 6.2. Read our review of WellorithmFlat-priced compounded semaglutide or tirzepatide injections in all 50 statesFrom$299/moafter intro offercompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, Sections 2 (Dosage), 6.1 (Clinical Trials Experience: Hair Loss) and 14 (Clinical Studies). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
- 3.Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417.
- 4.Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476.
- 5.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
- 6.Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT; STEP UP trial group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PMID: 40961952.
- 7.Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022. PMID: 36322838.
- 8.Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls Publishing. 2024. PMID: 28613598.
- 9.Kang DH, Kwon SH, Sim WY, Lew BL. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. PMID: 39623615.
- 10.Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026. PMID: 41998799.
- 11.Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disord. 2026. PMID: 42621629.
Related research
Zepbound Hair Loss: How to Stop It and What the Label Says (2026)
Zepbound's label lists hair loss in 4–5% of users vs 1% on placebo, mostly women. How to stop it, why a lower dose may not help, and when to see a doctor.
11 min read
Ozempic Hair Loss: What the Label and Diabetes Data Show (2026)
Ozempic's label lists hair loss only in postmarketing reports. What a 2026 type 2 diabetes study found, why Wegovy's rate is higher, and when to see a doctor.
10 min read
Do GLP-1s Cause Hair Loss? What All 5 Labels Say (2026)
Wegovy and Zepbound list hair loss in 3–6% of adults vs 1% on placebo; Ozempic, Rybelsus and Mounjaro give no rate. Why it happens and what helps.
8 min read
Does Semaglutide Cause Hair Loss? Ozempic vs Wegovy (2026)
Only Wegovy's label prints a semaglutide hair-loss rate (3.3% vs 1%). What Ozempic, Rybelsus and compounded semaglutide labels say, and what helps.
10 min read
GLP-1 + Finasteride or Minoxidil for Hair Loss: The Stacking Guide
GLP-1 telogen effluvium is real — 10-15% of patients shed during rapid weight loss. Stacking with finasteride 1 mg or topical minoxidil 5% can rescue regrowth. We review the published TE trials, finasteride PROPECIA pivotal, and the practical 6-month protocol.
12 min read
Ozempic Side Effects in Women: A Complete, Evidence-Based Guide
Ozempic side effects in women, explained: periods, PCOS and fertility, birth control, menopause, libido, hair loss, and weight regain after stopping.
9 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $79/mo
starting price
From $79/mo
sale price
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →From $129/mo
starting dose